Tf64 pet ct

Tau PET imaging involved the intravenous administration of 185 MBq (±10%) ¹⁸F-MK6240 with a 20-min acquisition time commencing 90 min post-injection. Aβ PET imaging involved the intravenous administration of 200 MBq (±10%) ¹⁸F-NAV4694 with a 20-min acquisition commencing 50 min post-injection. PET scans were acquired on one of two scanners: Philips TF64 PET/CT or a Siemens Biograph mCT. Philips TF64 PET/CT scans (n = 76) were reconstructed using LOR 3D Ramla algorithm and the smoothing parameter was set as sharp. Siemens Biograph mCT scans (n = 75) were reconstructed using an OSEM-3D with 4 iterations and 12 subsets. Low dose CT was obtained for attenuation correction. All participants had a structural 3T MRI on a Siemens Skyra scanner to obtain high-resolution T1 weighted anatomical magnetization-prepared rapid gradient echo (MPRAGE) sequences.

Tau PET imaging involved the intravenous administration of 185MBq (±10%) of ¹⁸F-MK6240 with a 20-min acquisition commencing 90-min post-injection. Aβ PET imaging involved the intravenous administration of 200MBq (±10%) of ¹⁸F-NAV4694 with a 20-min acquisition time commencing 50-min post-injection. PET scans were acquired on either a Philips TF64 PET/CT or a Siemens Biograph mCT. PET scans for each participant were performed on the same scanner at baseline and follow-up. Low dose CT was obtained for attenuation correction.

Radiotracers were manufactured in‐house (Austin Health, Melbourne, Australia). PET scans were acquired on either the Philips TF64 PET/CT or Siemens Biograph mCT. A low‐dose CT was obtained for attenuation correction.
Aβ PET imaging involved intravenous (IV) administration of 200 MBq (±10%) ¹⁸F‐NAV4694 with a 20‐minute acquisition time, commencing 50‐minutes post‐injection. Tau PET imaging involved IV administration of 185 MBq (±10%) ¹⁸F‐MK6240, with a 20‐minute acquisition time, commencing 90‐minutes post‐injection.